NASDAQ:APGE Apogee Therapeutics (APGE) Stock Price, News & Analysis $51.43 -0.36 (-0.70%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Apogee Therapeutics Stock (NASDAQ:APGE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Apogee Therapeutics alerts:Sign Up Key Stats Today's Range$50.93▼$52.2350-Day Range$45.25▼$59.9252-Week Range$14.19▼$72.29Volume198,032 shsAverage Volume503,497 shsMarket Capitalization$3.01 billionP/E RatioN/ADividend YieldN/APrice Target$78.50Consensus RatingBuy Company OverviewApogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Read More… Musk warns humanity: “Obsolete” (Ad)The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. Apogee Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks59th Percentile Overall ScoreAPGE MarketRank™: Apogee Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 476th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingApogee Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageApogee Therapeutics has received no research coverage in the past 90 days.Read more about Apogee Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Apogee Therapeutics are expected to decrease in the coming year, from ($2.57) to ($3.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apogee Therapeutics is -24.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apogee Therapeutics is -24.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApogee Therapeutics has a P/B Ratio of 6.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Apogee Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.90% of the float of Apogee Therapeutics has been sold short.Short Interest Ratio / Days to CoverApogee Therapeutics has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.Change versus previous monthShort interest in Apogee Therapeutics has recently decreased by 11.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApogee Therapeutics does not currently pay a dividend.Dividend GrowthApogee Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.90% of the float of Apogee Therapeutics has been sold short.Short Interest Ratio / Days to CoverApogee Therapeutics has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.Change versus previous monthShort interest in Apogee Therapeutics has recently decreased by 11.72%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.90 News SentimentApogee Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Apogee Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for APGE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Apogee Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,058,635.00 in company stock.Percentage Held by Insiders36.10% of the stock of Apogee Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.04% of the stock of Apogee Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apogee Therapeutics' insider trading history. Receive APGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APGE Stock News HeadlinesInsider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells 6,665 Shares of StockOctober 5, 2024 | insidertrades.comApogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $2,249,200.00 in StockOctober 5, 2024 | insidertrades.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Apogee Therapeutics (NASDAQ:APGE) Trading Down 4.1% - Time to Sell?October 20, 2024 | americanbankingnews.comApogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific MeetingOctober 16, 2024 | globenewswire.comApogee Therapeutics, Inc. (NASDAQ:APGE) Sees Large Decrease in Short InterestOctober 15, 2024 | americanbankingnews.comApogee Therapeutics (NASDAQ:APGE) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comApogee Therapeutics, Inc. (APGE): A Hot Stock to Buy NowOctober 7, 2024 | msn.comSee More Headlines APGE Stock Analysis - Frequently Asked Questions How have APGE shares performed this year? Apogee Therapeutics' stock was trading at $27.94 at the beginning of the year. Since then, APGE shares have increased by 84.1% and is now trading at $51.43. View the best growth stocks for 2024 here. How were Apogee Therapeutics' earnings last quarter? Apogee Therapeutics, Inc. (NASDAQ:APGE) announced its earnings results on Monday, August, 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.60). When did Apogee Therapeutics IPO? Apogee Therapeutics (APGE) raised $282 million in an initial public offering on Friday, July 14th 2023. The company issued 17,650,000 shares at a price of $15.00-$17.00 per share. Who are Apogee Therapeutics' major shareholders? Top institutional investors of Apogee Therapeutics include Waypoint Capital Advisors LLC (1.07%), Handelsbanken Fonder AB (0.02%), SG Americas Securities LLC (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Nimish P Shah, Michael Thomas Henderson, Carl Dambkowski and Jane Henderson. View institutional ownership trends. How do I buy shares of Apogee Therapeutics? Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Apogee Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apogee Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Netflix (NFLX) and Invesco QQQ (QQQ). Company Calendar Last Earnings8/12/2024Today10/23/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APGE CUSIPN/A CIK1974640 Webwww.apogeetherapeutics.com Phone650-394-5230FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price Target$78.50 High Stock Price Target$95.00 Low Stock Price Target$43.00 Potential Upside/Downside+52.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.05% Return on Assets-19.33% Debt Debt-to-Equity RatioN/A Current Ratio27.70 Quick Ratio27.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.50 per share Price / Book6.86Miscellaneous Outstanding Shares58,456,000Free Float28,754,000Market Cap$3.01 billion OptionableOptionable Beta2.75 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:APGE) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.